Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

53
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
53
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

3.3K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
3.3K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

2.2K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
2.2K
Chemical Synapses01:26

Chemical Synapses

9.5K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
9.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neurodegeneration in Glaucoma: Microstructural Magnetic Resonance Imaging Evidence Within and Beyond the Visual Pathway.

Investigative ophthalmology & visual science·2026
Same author

Sequential anterior ischaemic optic neuropathy associated with angioid streaks and sphenoid fibrous dysplasia.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie·2026
Same author

Is There a Causal Link Between GLP-1 Receptor Agonists and Non-Arteritic Anterior Ischaemic Optic Neuropathy? A Critique of the Clinical Evidence.

Clinical & experimental ophthalmology·2026
Same author

Non-Arteritic Anterior Ischaemic Optic Neuropathy and Its Masquerades: A Comprehensive Diagnostic Review.

Clinical & experimental ophthalmology·2026
Same author

Online Circular Contrast Perimetry: Validity and Repeatability of Home Performance.

Journal of glaucoma·2025
Same author

Outcomes After Acute Plasma Exchange for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Neurology·2025

Related Experiment Video

Updated: May 3, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

11.3K

Statins can induce myasthenia gravis.

Jesse Gale1, Helen V Danesh-Meyer2

  • 1Auckland District Health Board Ophthalmology Services, Auckland, New Zealand.

Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia
|January 18, 2014
PubMed
Summary

Statins, used for cardiovascular health, can rarely trigger autoimmune diseases like myasthenia gravis. This report details two new cases linked to atorvastatin, adding to the known association between statin use and autoimmune conditions.

Keywords:
AutoantibodiesHydroxymethylglutaryl-CoA reductase inhibitorsMyasthenia gravisNicotinicReceptorsT-lymphocyte subsets

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.2K

Related Experiment Videos

Last Updated: May 3, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

11.3K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.2K

Area of Science:

  • Immunology
  • Neurology
  • Pharmacology

Background:

  • * 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, commonly known as statins, are widely used for cardiovascular disease prevention.
  • * Autoimmune illnesses, such as myasthenia gravis, are rare but recognized side effects of statin therapy.

Observation:

  • * Two new cases of seropositive myasthenia gravis are presented, both developing approximately four weeks after initiating atorvastatin.
  • * This brings the total number of reported cases linking statins to myasthenia gravis to seven.

Findings:

  • * The study reviews existing literature to explore the relationship between statins, autoimmunity, and myasthenia gravis.
  • * Statins may potentially shift T-cell responses, dampening cell-mediated immunity while enhancing antibody-mediated humoral immunity.

Implications:

  • * This research highlights a potential mechanism by which statins could induce or exacerbate autoimmune conditions.
  • * Clinicians should be aware of the rare risk of autoimmune myasthenia gravis in patients taking statins, particularly atorvastatin.